ResMed Inc (RMD)vsWarby Parker Inc (WRBY)
RMD
ResMed Inc
$226.31
-0.82%
HEALTHCARE · Cap: $33.31B
WRBY
Warby Parker Inc
$23.38
+1.39%
HEALTHCARE · Cap: $2.86B
Smart Verdict
WallStSmart Research — data-driven comparison
ResMed Inc generates 519% more annual revenue ($5.40B vs $871.90M). RMD leads profitability with a 27.5% profit margin vs 19.0%. RMD trades at a lower P/E of 22.6x. RMD earns a higher WallStSmart Score of 70/100 (B).
RMD
Strong Buy70
out of 100
Grade: B
WRBY
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+14.4%
Fair Value
$303.30
Current Price
$226.31
$76.99 discount
Margin of Safety
-31314.3%
Fair Value
$0.07
Current Price
$23.38
$23.31 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 35.2%
Safe zone — low bankruptcy risk
Every $100 of equity generates 26 in profit
Keeps 28 of every $100 in revenue as profit
Every $100 of equity generates 46 in profit
Areas to Watch
No major concerns identified
0.0% earnings growth
Weak financial health signals
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : RMD
The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.
Bull Case : WRBY
The strongest argument for WRBY centers on Return on Equity. Profitability is solid with margins at 19.0% and operating margin at -4.5%. Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : RMD
No major red flags identified for RMD, but monitor valuation.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Piotroski F-Score, P/E Ratio. A P/E of 2338.0x leaves little room for execution misses.
Key Dynamics to Monitor
WRBY carries more volatility with a beta of 2.06 — expect wider price swings.
WRBY is growing revenue faster at 11.2% — sustainability is the question.
RMD generates stronger free cash flow (311M), providing more financial flexibility.
Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RMD scores higher overall (70/100 vs 34/100), backed by strong 27.5% margins and 11.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ResMed Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is an innovative leader in the direct-to-consumer eyewear market, redefining the optical landscape since its founding in 2010. By seamlessly blending a robust online platform with a growing number of physical retail outlets, the company enhances customer engagement while maintaining a focus on stylish, affordable prescription eyewear and sunglasses. Warby Parker's commitment to social impact is exemplified by its "Buy a Pair, Give a Pair" initiative, which fosters community support by providing eyewear to those in need. With a unique brand identity and forward-thinking marketing strategies, Warby Parker is well-positioned for continued expansion and enduring success in the competitive eyewear industry.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?